ArticleCancer management and research2012
New drugs and combinations for the treatment of soft-tissue sarcoma: a review.
Article in Cancer management and research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 26 citations in OpenAlex.
- DKI andBMC medical imaging · 2024Article
- Immunotherapy with nivolumab for the treatment of soft tissue sarcoma with pulmonary metastasis: A case report.Molecular and clinical oncology · 2020Article
- Deep Functional and Molecular Characterization of a High-Risk Undifferentiated Pleomorphic Sarcoma.Sarcoma · 2020Article
- Use of patient derived orthotopic xenograft models for real-time therapy guidance in a pediatric sporadic malignant peripheral nerve sheath tumor.Therapeutic advances in medical oncology · 2020Article
- Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma.BMC cancer · 2019Article
- Leiomyosarcoma of the stomach with metastasis to the liver: a case report with review of the literature.Future science OA · 2018Article
- Permanent interstitial 125I seed implantation as a salvage therapy for pediatric recurrent or metastatic soft tissue sarcoma after multidisciplinary treatment.World journal of surgical oncology · 2015Article
- Hybrid PET/MR imaging in two sarcoma patients - clinical benefits and implications for future trials.International journal of clinical and experimental medicine · 2014Article
- Molecular imaging for early prediction of response to Sorafenib treatment in sarcoma.American journal of nuclear medicine and molecular imaging · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcomas are a heterogeneous group of solid tumors arising from either soft tissues or bone, accounting for approximately 1% of all cancers in adults. Management of these diseases has changed little over the past 10 years, with the exception of treatment of gastrointestinal stromal tumors. Reasons for this stagnation include multiple histologies commonly grouped together in clinical trials limiting the understanding of benefit of treatment and limited investigation of molecular targeted therapies. More recently, advances in molecular pathogenesis, the advent of novel and targeted therapeutics, and increasing collaborations between sarcoma investigators has helped move the field forward in the right direction. Here, we review the recent data on novel agents tested for the management of adult soft-tissue sarcomas, excluding gastrointestinal stromal tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.